Autologous Stem Cell Transplantation

High-dose chemotherapy with rescue by the patient's own stem cells — indications, mobilization, conditioning, and outcomes in lymphoma, myeloma, and beyond

Key Points

• Autologous HSCT uses the patient's own stem cells to rescue the marrow after high-dose chemotherapy — there is no graft-versus-tumor effect, but also no GvHD.
• The main indications are relapsed/refractory diffuse large B-cell lymphoma (DLBCL), relapsed Hodgkin lymphoma (HL), and multiple myeloma (frontline consolidation).
• Stem cell mobilization with G-CSF ± plerixafor collects CD34+ cells from the peripheral blood by apheresis — an adequate CD34+ dose (≥2 × 10⁶ cells/kg) is required for engraftment.
• High-dose chemotherapy conditioning (e.g., BEAM, BCNU/Etoposide/Ara-C/Melphalan, or high-dose melphalan in myeloma) causes predictable myeloablation, mucositis, and organ toxicity.
• Treatment-related mortality is <2% at experienced centers — far lower than allogeneic HSCT — making auto-HSCT a safer procedure with a different risk-benefit profile.
• Relapse remains the dominant cause of treatment failure; CAR T-cell therapy has largely supplanted auto-HSCT for DLBCL failing first salvage, and its role continues to evolve.

What Is Autologous Stem Cell Transplantation?

Autologous hematopoietic stem cell transplantation (auto-HSCT) is a procedure in which a patient's own hematopoietic stem cells are collected, cryopreserved, and then reinfused after the patient receives high-dose chemotherapy (and sometimes radiation) that would otherwise cause irreversible and fatal bone marrow ablation. The stem cells serve purely as a "rescue" mechanism — they do not provide a graft-versus-tumor effect. The therapeutic benefit comes entirely from the ability to deliver substantially higher doses of chemotherapy than would otherwise be tolerable. This is the fundamental…

Indications

Auto-HSCT is appropriate when high-dose therapy can overcome chemotherapy resistance while the patient's stem cells are not themselves involved by the malignancy (or can be cleansed of tumor contamination). **Diffuse Large B-Cell Lymphoma (DLBCL):** The landmark PARMA trial (1995) established auto-HSCT as standard of care for relapsed/refractory (R/R) DLBCL that is chemosensitive to salvage therapy. Patients with R/R DLBCL who achieve a partial or complete remission with platinum-based salvage chemotherapy (R-ICE, R-DHAP, R-GDP, R-ESHAP) proceed to auto-HSCT consolidation. However, for…

Stem Cell Mobilization and Collection

Before high-dose therapy can be administered, sufficient numbers of CD34+ hematopoietic stem cells must be collected from the patient's peripheral blood by apheresis and cryopreserved for later reinfusion. This process — mobilization — moves stem cells from their normal bone marrow niche into peripheral blood where they can be collected. **Mobilization regimens:** *G-CSF alone:* Filgrastim 10–16 mcg/kg/day subcutaneously for 4–7 days mobilizes CD34+ cells from marrow into blood through CXCR4/CXCL12 disruption. Apheresis begins when peripheral blood CD34+ count reaches ≥10–20 cells/μL…

High-Dose Conditioning Regimens

The conditioning regimen in auto-HSCT is selected based on the underlying malignancy, prior therapy received, and organ function. Unlike allogeneic HSCT, the purpose is purely cytoreductive — there is no graft rejection to overcome. **BEAM (carmustine [BCNU] + etoposide + cytarabine + melphalan):** The most widely used regimen in lymphoma (both Hodgkin and diffuse large B-cell). Carmustine 300 mg/m² Day -6; etoposide 100–200 mg/m²/day Days -5 to -2; cytarabine 200 mg/m² twice daily Days -5 to -2; melphalan 140 mg/m² Day -1. BeEAM (bendamustine replacing carmustine) is used at some centers to…

The Transplant Course and Engraftment

**Stem cell infusion (Day 0):** Cryopreserved stem cell bags are thawed at the bedside in a 37°C water bath and infused rapidly through a central venous catheter. DMSO cryoprotectant causes a characteristic garlicky odor (from patients' breath and skin) and occasionally causes nausea, hypotension, bradycardia, or rarely anaphylaxis during infusion. Premedication with diphenhydramine and dexamethasone is standard. Large volumes of DMSO (>1 g/kg) are divided across multiple infusion sessions to limit toxicity. **The nadir period (Day +5 to Day +14):** After conditioning and before engraftment,…

Complications and Toxicity Management

**Mucositis:** Chemotherapy-induced oral and GI mucositis is the most debilitating and universal complication of auto-HSCT. Graded 0–4 by WHO or NCI CTCAE; Grade 3–4 (inability to eat/swallow, requiring IV nutrition) occurs in 30–60% depending on regimen. Management: bland diet, salt-and-soda rinses, topical anesthetics (viscous lidocaine), systemic opioid analgesia, and total parenteral nutrition (TPN) or nasogastric tube feeds if oral intake is insufficient. Palifermin (keratinocyte growth factor; Kepivance) IV × 3 days before and after conditioning reduces Grade 3–4 mucositis in certain…

Post-Transplant Maintenance and Long-Term Outcomes

**Lymphoma:** For HL, brentuximab vedotin maintenance × 16 cycles after auto-HSCT improves PFS in high-risk patients (AETHERA trial: median PFS 43 months BV vs. 24 months placebo). For DLBCL, no maintenance has demonstrated OS benefit after auto-HSCT, though rituximab maintenance and novel agents (polatuzumab vedotin, lenalidomide) are being studied. **Multiple myeloma:** Lenalidomide maintenance after auto-HSCT is standard of care and significantly extends PFS and OS (CALGB 100104, IFM 2005-02, Myeloma XI). Continues until disease progression or intolerance. For high-risk myeloma (del(17p),…